PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/VRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts provides unique perspectives on applying an evidence-based, patient-centered approach to psoriatic disease care. Upon completion of this activity, participants will be able to: Describe the pathophysiology and clinical presentations of psoriasis and psoriatic arthritis (PsA), Employ strategies to screen patients for comorbidities associated with psoriatic disease, Discuss current and emerging treatment options for psoriatic disease in the context of mechanism of action, efficacy, safety, and optimal clinical use, Design individualized treatment plans for patients with psoriatic disease based on evidence-based guidelines, safety and efficacy of pharmacologic treatment options, disease severity, and patient quality of life (QoL) factors.

Go online to PeerView.com/NDJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a stroke and vascular neurologist shares a patient case to provide clinical relevance and a practical exploration of the latest advances in the diagnosis and treatment of patients with a large hemispheric infarction (LHI). Upon completion of this activity, participants should be better able to: Apply current evidence-based guidelines to diagnose and treat patients with an LHI, Identify clinical characteristics associated with increased risk of cerebral edema in patients following an LHI, Summarize the benefits and limitations of current and emerging therapeutic strategies to prevent cerebral edema in patients following an LHI.

Go online to PeerView.com/WXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses practical strategies for identifying and managing axial spondyloarthritis (axSpA) in clinical practice. Upon completion of this activity, participants should be better able to: Identify axSpA in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences, Recognize the importance of collaborating with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/VJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts explore the potential of the next wave of novel HER2-targeting therapies in various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. Watch as the panel share their insights into the data that support therapeutic targeting of HER2 and consider other critical research questions and future directions. Upon completion of this activity, participants should be better able to: Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, and non–small cell lung cancers, Evaluate the characteristics, mechanisms of action, and efficacy/safety evidence of established and emerging HER2-targeted agents for the management of patients with advanced HER2-expressing or ERBB2-mutant cancers, Identify novel approaches to overcome mechanisms of resistance to HER2-targeted therapies, Integrate the latest HER2-targeted therapies into individualized treatment plans for patients with advanced HER2-expressing or ERBB2-mutant breast, gastric, colorectal, and non–small cell lung cancers, either in the context of clinical practice or through clinical trial participation.

Go online to PeerView.com/KFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Dr. Heather McArthur provides a brief recap of how the emergence of checkpoint inhibitor therapy in TNBC has changed the management of this challenging subtype of breast cancer, and what some of the unanswered questions and controversies are that ongoing research is aiming to answer. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.

Go online to PeerView.com/ZYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in women’s health discusses current and emerging therapies for endometriosis and uterine fibroids. Upon completion of this activity, participants should be better able to: Summarize the diagnostic evaluation for uterine fibroids and endometriosis including ultrasound, lab tests and other imaging tests, Recognize the benefits and limitations of current and emerging options for medical management of endometriosis and uterine fibroids, Discuss recent clinical data for the management of endometriosis-associated pain and uterine fibroids, Employ strategies to actively integrate current clinical evidence- and practice-based recommendations for the management of patients with endometriosis and uterine fibroids.

Go online to PeerView.com/VCA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on heart failure discusses strategies for recognizing and diagnosing heart failure in patients, including the role of natriuretic peptides as clinical biomarkers. Upon completion of this activity, participants should be better able to: Review recommendations offered in current evidence-based guidelines intended to encourage early recognition and timely diagnosis of patients with heart failure, Apply diagnostic and therapeutic strategies using BNP and NT-proBNP as clinical biomarkers to guide the care of patients with heart failure, Evaluate evidence-based strategies for identifying and treating heart failure in patients with reduced ejection fraction.

Go online to PeerView.com/RXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonology discusses key issues in the diagnosis and treatment of patients with uncontrolled persistent asthma. Several case vignettes provide insights on assessing phenotype/endotype and eligibility for biologic therapy in these patients, in the context of common comorbidities and other patient-, disease-, and treatment-related factors. Upon completion of this activity, participants should be better able to: Describe the role of the type 2 inflammatory cascade in uncontrolled persistent asthma and the implications for treatment, Evaluate patients with asthma for symptom severity, phenotype/endotype, exacerbation risk, and eligibility for biologic therapies, Employ the latest clinical data on efficacy and safety of biologic therapies to the treatment of patients with uncontrolled persistent asthma, Use strategies to engage patients in shared decision-making to improve outcomes and quality of life.